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Abstract: Modern genetic analysis has shown that most polymorphisms associated with 
human disease are non-coding. Much of the functional information contained in the  
non-coding genome consists of cis-regulatory sequences (CRSs) that are required to 
respond to signal transduction cues that direct cell specific gene expression. It has been 
hypothesised that many diseases may be due to polymorphisms within CRSs that alter their 
responses to signal transduction cues. However, identification of CRSs, and the effects of 
allelic variation on their ability to respond to signal transduction cues, is still at an early 
stage. In the current review we describe the use of comparative genomics and experimental 
techniques that allow for the identification of CRSs building on recent advances by the 
ENCODE consortium. In addition we describe techniques that allow for the analysis of the 
effects of allelic variation and epigenetic modification on CRS responses to signal 
transduction cues. Using specific examples we show that the interactions driving these 
elements are highly complex and the effects of disease associated polymorphisms often 
subtle. It is clear that gaining an understanding of the functions of CRSs, and how they are 
affected by SNPs and epigenetic modification, is essential to understanding the genetic 
basis of human disease and stratification whilst providing novel directions for the 
development of personalised medicine. 
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The importance of gene regulation cannot be overstated; the evolution of complex multicellular 
organisms whose cells possess identical genomes, yet exhibit phenotypic and functional diversity, 
coincides with the evolution of complex gene regulatory systems capable of controlling differential 
gene expression [1,2]. Further, multicellular life must have the ability to regulate its transcriptome in 
response to extracellular signals from the environment, and surrounding cells if it is to develop, adapt 
and survive. To this end eukaryotes have evolved a repertoire of extracellular signals and receptors 
which activate diverse signal transduction pathways ultimately resulting in the regulation of specific 
genes through recruitment of transcription factor (TF) complexes [3]. Central to this process in many 
genes is the involvement of cis-regulatory sequences (CRSs); non-coding functional regions of DNA 
which mediate TF binding and regulate transcription [4]. 
Interest in cis-regulatory sequences has intensified since the human genome sequence was first 
mapped [5,6] and subsequently shown to only contain 20,000?25,000 protein coding genes [7]; far 
fewer than was previously anticipated, leaving ~97% of the genome with no predicted coding function. 
Consequently, comparative genomics [8,9] has been used to demonstrate that conservation of  
non-coding DNA regions between evolutionarily divergent species is a powerful tool for the prediction 
of cis-regulatory sequences [10?13] including promoter and enhancer regions, insulators and locus 
control regions (reviewed; [14]). More recently, the international consortium ENCODE published a 
series of papers highlighting that 80.4% of the human genome functions in some form of biological 
process, and conservative estimates suggest that there may be 4.5 times more functional information 
within the genome than that which encodes proteins [15]. 
Given the fundamental role CRSs play in gene regulation, and the necessity for precise regulation to 
orchestrate correct development and function, it comes as no surprise that variation within CRSs is 
emerging as a major source of disease susceptibility in human populations [16]. Meta-analysis of 
multiple genome wide association (GWA) studies [17,18] indicates that 88% of disease-associated 
single nucleotide polymorphisms (SNPs) lie in intronic or intergenic regions [19]. More specifically, 
71% of disease-associated SNPs (including SNPs in linkage disequilibrium) lie in non-coding 
regulatory regions identified by ENCODE [15]. Hence polymorphisms of non-coding regulatory 
regions are disproportionately linked to human disease likely through mechanisms involving  
aberrant gene regulation. In principle, these gene regulation aberrations will not only impact an 
?????????????????????????????????????????????????????????????????????????????????????????????????????????ng 
biochemical differences. 
A significant challenge for molecular genetics is therefore to: (1) determine the tissue-specific 
nature of cis-regulatory relationships within 3 dimensional paradigms; (2) locate interacting partners of 
CRSs (3) apply computational and experimental approaches to understand how they function in 
Biology 2013, 2 66 
 
regulatory networks; (4) evaluate the effect of endogenous CRS variation in the context of  
cellular signalling and (5) determine the role that CRS variation plays in human disease and drug 
response stratification. 
2. The Importance of Non-Coding DNA 
As a prerequisite to understanding developments within the field of CRS research we have outlined 
some basic aspects of eukaryotic transcription with respect to transcriptional machinery and  
cis-regulatory functions (Figure 1). To appreciate the value of studying non-coding DNA, and its role 
in gene regulation, we must evaluate its importance with respect to evolution and development and 
determine its pathological potential. 
2.1. cis-Regulatory Sequences Have Shaped Human Evolution and Development 
A critical feature of CRSs is the modular nature by which they regulate gene expression [20]. Thus 
tissue-specific (spatial) and developmental stage-specific (temporal) gene expression can be controlled 
by specific CRS-mediated TF-complex binding. The apolipoprotein E (APOE) locus is a well 
characterised example of a gene that is regulated by multiple flanking CRSs that direct differential 
expression to liver cells [21,22] or skin cells [23,24], or astrocytes, macrophages and adipocytes [24,25]. 
Consequently, the effects of mutations in CRSs can be limited to particular cell types or developmental 
stages making them less pleiotropic than coding mutations. The relative lack of pleiotrophism makes 
CRSs strong candidates for driving evolution through mutation as well as inducing susceptibility to 
late onset disease. For example a CRS SNP located upstream of the DARC promoter, which codes a 
human receptor important for the reception of immune system signals [26?28], abolishes expression of 
the receptor in erythrocytes [29,30]. This SNP confers complete resistance to malaria [31,32] by 
preventing Plasmodium spp. parasites entry to erythrocytes due to the lack of the DARC-coded 
receptor [33,34]. Importantly, the SNP has little or no deleterious effects in other DARC expression 
domains. Another example is HACNS1, a highly conserved non-coding sequence, which has been 
identified to contain human-specific polymorphisms that result in the differential limb patterning 
observed between humans and non-human primates [35]. 
2.2. cis-Regulatory Sequences are Implicated in Human Pathologies  
With respect to human pathologies it was shown that a non-coding regulatory SNP located near the 
?-globin gene cluster creates a new TF consensus sequence for GATA-1 augmenting the activation of 
the gene cluster and causing Thalassemia in affected individuals [36]. Further, very recent data 
concerning the transcription factor 7-like (TCF7L2) locus has utilised the results of GWA studies, 
identifying variation within the TCF7L2 intronic regions as highly associated with risk of type 2 
diabetes, and shown that the associated variation is located within a cis-regulatory region [37]. 
Moreover it has been discovered that Hirschsprung disease risk is associated with variation within an 
enhancer region of the receptor tyrosine kinase RET [38,39]. While coding mutations in RET were 
causative in a small portion of cases the authors also found that variation within a CRS of RET intron 1 
resulted in a significant decrease in RET expression [38,39]. 
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Figure 1. Graphic representation of eukaryotic transcriptional machinery. (A) Basal 
eukaryotic transcriptional machinery; members of the transcription factor II (TFII) family 
of proteins associate with RNA polymerase II (RNApolII) in an ordered manner to form 
the pre-initiation complex. The core promoter region, containing transcription factor 
binding sites (TFBS) and the transcriptional start site, is bound by the pre-initiation 
complex and RNApolII is directed to begin transcription of target genes. (B) cis-regulatory 
DNA sequences modulating eukaryotic transcription. Distant cis-regulatory sequences 
(CRSs), such as enhancers and silencers (located up to 1Mbp from the target promoter), 
associate with additional TFs (Xn) and form indirect interactions with the target promoter. 
Subsequently, transcriptional outputs are modified depending on the nature of the 
associated CRS; increases in transcript quantity (enhancer function?green arrows) or 
reduction/abolition of transcription (silencer function?red T-bars). In order for 
enhancer/silencer sequences to interact with target promoters DNA must be modified to 
?loop out? the interspaced DNA. Other recognised classes of regulatory sequences include 
insulators: Barrier-form insulators prevent chromatin condensation from repressing active 
regulatory regions setting up regulatory boundaries; Enhancer-blocking (EB) insulators 
maintain the specificity of CRS interactions by blocking regulatory sequences from 
impinging on neighbouring genes. Finally, locus control regions are described as regions 
containing multiple CRSs, they function in concert to confer correct temporal and/or 
spatial specificity of the target gene. 
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2.3. Rationale for cis-Regulatory Sequence Research 
It is clear from these examples that CRSs play a vital role in evolution, development and human 
disease, indeed preeminent conjectures concerning the importance of CRSs to evolution and 
development through gene regulation were made ~40 years ago by Jacob and Monod [40], Britten and 
Davidson [41,42] and King and Wilson [43]. However, despite the wealth of evidence which has been 
mounting in recent years CRSs remain relatively poorly understood. This is due in part to decades of 
exon-focused research, which by comparison has more easily definable and testable entities. 
Intriguingly, computational analysis has shown that 87% of the conserved genome between humans 
and mice (>70% identity over 100 bp) is non-coding which highlights the potentially massive pool of 
unexamined functional DNA present within the genome [44]. One of the major challenges to 
examining CRSs is their identification and publication of the human genome sequence [5,6] has 
proved enormously helpful in addressing this issue. Moreover the collaborative efforts of the 
ENCODE project has marked a huge step towards elucidating the functional regulatory landscape of 
the human genome through systematic CRS identification using a number of well characterised 
computational and experimental paradigms which we have summarised below [15]. 
3. cis-Regulatory Sequence Identification?Comparative Genomics 
Comparative genomics has emerged as a powerful tool for the discovery of CRSs and relies on the 
basic principle that regulatory functional sequences are under purifying selection and cross-species 
sequence comparisons can highlight this conservation. It is important to note that, while many CRSs 
regulate target gene expression through TF binding and recruitment to promoters, predicted TF binding 
motifs do not represent reliable candidate sequence motifs for the identification of CRSs due to their 
high degeneracy and wide-spread distribution in the genome. Instead we may broadly consider two 
approaches assessing genome-wide sequence conservation: evolutionary distant species comparisons 
and evolutionarily related species comparisons. 
3.1. Evolutionary Distant Species Comparisons 
In the first case, the availability of genome sequences from birds, fish and reptiles allow researchers 
to identify putative CRSs with functions critical to vertebrate development by way of pair-wise 
comparison to mammalian genomes. This approach has been highly successful for identifying CRSs, 
even prior to the availability of genome sequences for so many vertebrates [45], such as those involved 
in the tissue-specific expression of embryogenesis genes related to: cardiac development [46]; limb 
patterning [13,47,48] and brain development [13,48,49]. Indeed a common feature of CRSs identified 
by this method is that they are non-randomly located in gene deserts [12,50] adjacent to genes with 
developmental functions [49]. 
Unquestionable then is the potential importance of distant comparative approaches, clearly capable 
of locating vertebrate developmental gene-related CRSs, but there are a number of important caveats 
to consider. Firstly, altering the parameters of this strategy has been shown to cause estimations of 
CRS numbers to vary between 1,400 [49] and 5,700 [51], suggesting that the method is insensitive and 
misses many CRSs since these estimations are an order of magnitude lower than the predicted number 
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of human genes [7]?? ?????????????? ????? ?????? conservation is likely to be the result of a shared 
biological process between the species under comparison; hence this method is unable to identify 
CRSs involved in processes which evolved subsequent to the divergence of the species in question. 
Finally, if such comparisons are used between less divergent species such as human-rodent the relaxed 
parameters (>70% identity over 100 bp) will throw up large numbers of false positive results. 
3.2. Evolutionary Related Species Comparisons 
In the second case, researchers can identify CRSs more likely related to higher vertebrate health by 
comparing less distant species with more stringent conservations parameters. Specifically, typical 
conservation parameters between human-chicken or human-frog comparisons are >70% identity over 
100 bp. However Bejerano et al., (2004) explored the use of human-rodent comparisons at parameters 
of 100% identity over 200 bp [52]. Unsurprisingly, they found a smaller set of putative CRSs as 
compared to Woolfe et al., (250 [52] and 1,400 [49] respectively), however investigation of some of 
???????ultra-?????????? sequences has proved, in principle, that the method is capable of identifying 
modulators of gene transcription [48,53,54]. Interestingly, the method was further assessed in 
combination with human-fugu comparisons, whereby the authors were able to predict enhancer activity 
of sequences very successfully (~60% of identified sequences showed enhancer capacity) by coupling 
?????? conservation (human-fugu) with ultra-conservation (human-rodent, described above) [13]. 
However, subsequent investigation into ultra-conservation comparisons has lead some researchers to 
conclude that overall sequence conservation, as opposed to ultra-conservation, is a good predictor of 
CRSs functionality [55]. 
Consequently, ultra-conservation comparison techniques do suffer as a product of their design; they 
are likely to identify only small subsets of CRSs, and not only miss numerous other CRSs but also 
cannot be utilised as a large-scale prediction method [11]. Further, the parameters required to fulfil the 
?ultra-conservation? label mean that many predicted CRSs are also identified by evolutionary 
divergent comparisons [11]. Likely, even with the manifestation of well characterised highly accurate 
computation models to predict CRSs, we must acknowledge that computational data alone cannot 
provide extensive evidence as to biological function. Consequently, parallel experimental approaches 
have been developed to complement computational prediction of CRSs to good effect. 
4. cis-Regulatory Sequence Identification?Experimental Approaches 
In response to the stated drawbacks of computational conservation-based CRS prediction  
methods, well developed strategies now exist which allow researchers to identify CRSs in a 
conservation-independent manner (reviewed [56]). One particular reason for this is the observation 
that ~50% of experimentally validated CRSs do not show sequence conservation [57], and, depending 
on the tissue type under investigation, enhancers can been significantly non-conserved [58]. 
4.1. Transcriptional Associations: Chromatin Immunoprecipitation Techniques 
A number of the experimental paradigms for CRS identification originate from the exploitation of 
an indirect physical association between the CRS and its target promoter via TF-complexes and 
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transcriptional co-activators such as p300 [14,59]. Researchers begin determining these interactions  
by cross-linking chromatin with formaldehyde, capturing endogenous DNA-protein interactions  
within the nucleus, and subsequently shearing it into smaller pieces by sonication or enzymatic  
digest. Samples are enriched for DNA showing an association with specific ???s, co-activators or 
histone-modifications associated with enhancers (e.g., H3K4me1) or silencers by immunoprecipitation 
with antibodies specific to the TF, co-activator or histone-modification. The principle technique is 
called chromatin immunoprecipitation (ChIP), and the resultant enriched samples can be analysed by 
hybridisation to microarrays (ChIP-chip) [60,61] or by deep sequencing the entire enriched DNA 
sample (ChIP-seq) [62,63]. Results are analysed for DNA sequences which are over represented in the 
????????? ????????? ?????????????? ????? ????? ???? ??????? ??????????? ????? ????? ??????? ??-activators and 
therefore involved in transcriptional regulation. This method can also be used on restricted cell 
populations by initially micro-dissecting specific tissue regions, ChIP results then provide an 
immediate indication of the tissue-specific activity of identified CRSs [64]. 
4.2. Active Chromatin Signatures: DNaseI Hypersensitivity and Formaldehyde-Assisted Identification 
of Regulatory Elements 
Another approach to discovering CRSs employs the fact that functional non-coding sequences are 
???????????????????????? chromatin conformations, induced through TF binding, making these stretches 
of DNA more sensitive to DNase I activity [65]. DNase I hypersensitivity (DHS) approaches can again 
be combined with microarrays or deep sequencing to i???????? ???????? ??? ???? ????? ??? ?????? 
chromatin structure indicative of TF binding and presumed regulatory potential [66,67]. Of particular 
interest, this technique is capable of detecting hypersensitivity differences which result from 
polymorphisms within the genetic code, highlighting the potential for polymorphic variation in CRSs 
to impact gene regulation and by extension disease [68]. Further, DHS sites are known to be enriched 
for non-coding disease-associated genetic variants and commonly map to disease-associated loci [69]. 
Consequently, DHS data can be highly predictive of disease-associated regulatory networks including 
causative CRSs and interacting proteins [69,70]. FAIRE (formaldehyde-assisted identification of 
regulatory elements) is similar to the DNase I hypersensitivity technique, in that it exploits open 
??????????????????????????????mechanical shearing after formaldehyde cross-linking to non-selectively 
identify functional regulatory DNA regions [71]. Both of these methods can provide researchers with 
fast, cost effective results. Combined with well organised comparative genomic analysis CRSs can 
often be inferred providing a reliable basis for further study. 
4.3. Chromosome Interactions: Chromosome Conformation Capture Strategies 
The above techniques identify either DNA which associates with transcriptional regulatory proteins 
(ChIP) or DNA which is putatively active in the binding of transcriptional regulatory proteins (DNase, 
FAIRE), but neither is able to remote chromatin interactions nor do they provide information relating 
to the 3-dimensional structure of the genome. Development of chromosome conformation capture  
(3C) [72], and derived techniques (4C, 5C and Hi-C [73] (see [74] and [75] for review)), overcome this 
hurdle on the premise that CRSs and promoters must indirectly interact across large regions of the 
genome. A consequence of these long distance interactions is that, following cross-linking and 
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shearing, DNA can be covalently ligated to sequences in close 3-dimensional proximity (proximity 
ligation). The experimental output then identifies interactions between DNA sequences, which may 
normally be separated by up to 1 Mb, being sequenced together more frequently as a result of a 3D 
chromatin interaction. A drawback of 3C, 4C and 5C is that they are all biased towards a particular 
locus, or set of loci, under investigation. 
Conversely, Hi-C is both genome-wide and unbiased in its identification of long distance chromatin 
interactions; by incorporating biotinylated residues into the fragment ends after digestion of  
cross-linked DNA streptavidin can be used to select for sequences in close proximity which are 
subsequently analysed [73]. Further advancements towards the functional annotation of the genome 
have resulted in the development of the technique ChIA-PET (chromatin interaction analysis by 
paired-end tag sequencing) [76,77]. Similar in methodology to Hi-C, but requiring an interacting 
protein for sample enrichment by immunoprecipitation before proximity ligation, ChIA-PET is seen as 
a promising alternative to ChIP-Seq since it is capable of identifying both TFBSs and chromatin 
structure within purified sequences [77,78]. 
4.4. Towards a Map of the ?????????????????????????????: The ENCODE Consortium 
The ENCODE consortium represents an international project aimed at identifying all the functional 
elements in the human genome using a combination of computational and experimental approaches [15] 
(some of which are outlined above). Data generated by the project is available on the UCSC genome 
website [79,80]; customisable tracks can be selected to view chromatin modification signatures, DNase 
I hypersensitivity, FAIRE analysis, TF binding sites, transcriptional start sites and DNA methylation 
patterns for particular genomic regions within a number of different cell type. Consequently, 
ENCODE data is likely to represent the starting point for the majority of CRS investigations of the 
future; a vast database of the regulatory landscape of the genome will provide researchers with 
immediate indications of the regulatory capacity of selected regions. Further, work in progress by 
ENCODE to complete genome wide chromosome conformation maps will provide researchers with 
invaluable insights into long distance DNA sequences interactions. 
However, we must highlight some caveats of ???????s three tiered cell type strategy [15]. The 
exclusion of many important primary cell types, such as neuronal cells, has undoubtedly resulted in 
many CRSs going undetected due to both the context dependent nature of CRSs and their inducibility 
by cellular signalling events (see: A question of specificity? for more information). This ultimately 
means that while ENCODE data at UCSC will serve as a platform for much CRS research the lack of 
positive functional information for many highly conserved sequences does not yet persuasively 
indicate that they are not regulatory but that the particular cell types or specific stimuli used to ascribe 
functionality have yet to be ascertained. 
5. Analysis of cis-Regulatory Sequences 
Two standard approaches used to evaluate putative CRSs are transgenic animal-based reporter gene 
assays and cell-based reporter gene assays. By providing qualitative and quantitative information 
(respectively) about CRSs of interest these techniques are widely used in the confirmation of putative 
regulatory sequences. A schematic representation of CRS research workflow summarises how Sections 
3, 4 and 5 are commonly implemented (Figure 2). 
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Figure 2. General experimental workflow of cis-regulatory sequence studies. (A) 
Numerous well characterised methods for CRS identification exist including computational 
and experimental approaches (described in main text). (B) Identified target sequences 
(boxed?grey) are reliably amplified via polymerase chain reaction (PCR) using specific 
primers (arrows). (C) Target sequences (putative CRSs) are cloned into a variety of 
reporter plasmid constructs, including luciferase, LacZ and fluorescent protein derivatives 
(e.g., GFP). Typically reporter plasmids are sequenced to ensure sequence integrity. (D) 
Reporter plasmids may be introduced to cell culture-type systems by transfection or into 
animal embryos by cytoplasmic or pronuclear injection. (E) Depending on the assay type a 
number of experimental outputs are obtainable: cell culture assays can provide quantitative 
analysis of target CRSs via luminosity readings (e.g., luciferase) and are particularly useful 
for pharmacological studies (see Figure 3); animal/embryo studies can provide qualitative 
explanations of where and when the target CRS is active during development. 
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5.1. Transgenic Animal Reporter Assays 
Using analysis of transgenic animals the CRS of interest is typically cloned upstream of a reporter 
gene such as LacZ [81] or GFP, and the resultant construct is injected into fertilized animal embryos 
typically derived from species such as zebrafish, Xenopus, chicken or mouse. Subsequently, animals 
???????????????????????????????????????????-galactosidase activity via X-Gal staining or GFP expression 
with fluorescent microscopes. This method provides the chance to assess the ability of the CRS of 
interest to drive tissue-specific expression of the reporter gene; a central requirement of CRSs in  
gene regulation. 
Transgenic analysis is considered by many researchers to ?????????? ???? ?????? ????????? for 
confirming the tissue specificity of a candidate CRS. A number of hugely successful examples of its 
use exist [13,48,49,55], in particular Pennacchio and colleagues examined 167 putative CRSs, 
identified through comparative genomics, and established that 45% of the candidate sequences 
supported tissue specific expression of LacZ in developing mouse embryos [13]. Indeed the majority 
of deeply conserved CRSs identified to date function in early development [35], and consequently 
LacZ expression is often assessed in embryonic mice [13]. Within our lab CRSs have also been tested 
for tissue-specific expression in adult mice where our focus relates to their impact in adult neuronal 
gene regulation as opposed to developmental programmes [82]. 
Transgenic animal reporter assays alone are not sufficient to confirm the identity of a target 
sequence as a specific regulator of the proposed target gene. Subsequent in-situ hybridisation or 
immunohistological staining are required to demonstrate that putative CRS-driven LacZ expression  
co-localises with the endogenous transcript or endogenous protein. Further it is noteworthy that 
pronuclear injection creates a random insertion of reporter constructs, consequently at least 2 different 
transgenic lines with corroborating expression patterns are required. 
5.2. Cell-Based Reporter Gene Assays 
In addition to qualitative cell specific analysis it is useful to analyse the effects of SNPs or signal 
transduction cues on the quantitative activity of candidate CRSs. Putative CRSs are typically PCR 
amplified and cloned into reporter constructs, upstream of quantifiable reporter genes such as firefly 
luciferase. These constructs are then transfected into transformed cell lines or primary cell cultures. 
This method ultimately determines whether the CRS of interest is capable of eliciting a significant 
effect on the expression of the reporter gene, indicating its potential to function in gene regulation or to 
determine polymorphic effects. 
We have used primary cell-based reporter gene assays to establish the presence of a highly 
conserved CRS (BE5.2) which functions as a silencer of the brain derived neurotropic factor (BDNF) 
promoter IV that plays a role in modulating mood [83]. Further, the quantitative nature of this method 
has been employed by our group to analyse the impact of allelic variation on CRS function; we have 
demonstrated significant allele-dependent changes in the activity of the galanin gene enhancer 
(GAL5.1) in primary hypothalamic neurons using luciferase reporter assays [82]. 
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6. Beyond Identification: cis-Regulatory Sequence Characterisation 
CRS characterisation studies are becoming increasingly pertinent in the wake of large scale,  
high-throughput, genome-wide identification projects (e.g., ENCODE). Vast CRS identification, even 
when coupled to the aforementioned methodologies, falls short of characterising the intricate signal 
transduction events which control CRS function. A molecular-level understanding of CRS functions is 
therefore essential if we hope to exploit them clinically and understand how regulatory polymorphisms 
impact susceptibility to many common human pathologies. The logic of CRS characterisation studies 
by pharmacological perturbations (as discussed below) is graphically represented (Figure 3). 
Figure 3. Characterisation of cis-regulatory sequences. 
 
6.1. Dissecting the Impact of Cellular Signalling 
Due to its quantitative output cell-based reporter gene assays provide a means to investigate the 
cellular systems that modulate the activity of a given CRS through the manipulation of intracellular 
transduction pathways or ligand-receptor interactions by pharmacological means. The function of 
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????? ???????? ??? ???? ????????????? ???? ???????? ??? ????? ???? ??-activators [4]?? ????? ???? ???????? ???
regulation though mechanisms such as extracellular receptor activation, cytoplasmic serine kinase 
activation and intracellular proteolysis activity [84]. Consequently, cell cultures may be treated with a 
host of pharmacological agents to elucidate the precise biochemical requirements for CRS-mediated 
gene regulation. For example, we have previously demonstrated the ability of GAL5.1 to respond to 
PKC activation [82] and MAPkinase signalling as a necessary cue to the activation of a CRS contained 
within intron 2 of the CNR1 gene [85]. Similar work has been conducted by the Barolo laboratory as 
they set about defining the biochemical pathways which regulate the Drosophila sparkling (spa) 
enhancer [86]. Research of this nature is required to define the parameters of CRS function, without 
knowing the precise events which precede the involvement of a CRS in gene regulation we cannot 
begin to define their role in disease or produce clinical strategies based on their perturbation. 
It is important to determine the relevance of pharmacological CRS manipulation to endogenous 
gene expression by assessing the effects of these pharmacological agents on the endogenous mRNA 
levels in parallel using quantitative reverse transcriptase PCR (qrtPCR). This combination of luciferase 
reporter gene assay and qrtPCR strengthens the argument for a CRS????????????????????????????????????
expression. For example using qrtPCR we demonstrated the induction of the TAC1 gene in primary 
dorsal root ganglia (DRG) cells by MAPkinase agonism or noxious stimulation by capsaicin. 
However, as assessed by luciferase reporter assay the TAC1 promoter alone was unable to respond to 
these stimuli. Only by combining the TAC1 promoter with a remote and highly conserved enhancer 
region called ECR2 could we induce a response from the TAC1 promoter that was consistent with the 
response of the endogenous TAC1 gene. This provides evidence of a requirement for enhancer-promoter 
synergy at the TAC1 locus within DRG neurons following noxious induction [87,88]. 
Rapid development of CRS identification methods and collaborative efforts by the ENCODE 
consortium have placed an increasing emphasis on the characterisation of newly identified CRSs. Our 
schematic (Figure 3) shows the layers of a eukaryotic cell (from the extracellular to the nuclear) 
depicting a simplified cascade of cellular events from: extracellular cues binding to/transporting 
through cellular receptors; to intracellular transduction pathways; culminating in the production/activation 
of TFs and ultimately modulating gene transcription accordingly. 
Using the previously discussed cell culture assays we highlight how pharmacological treatments 
aimed at specific cellular processes can potentially alter the activity of a CRS under investigation. For 
example, in the middle case treatment 2 has defined that the CRS in question is regulated by a 
particular signal transduction event. Further analysis would eventually determine the specific cellular 
conditions which precede the recruitment of this CRS to transcription of its target gene. Indeed, this 
scheme also highlights the potential of such an experimental paradigm to explore the impact of CRS 
polymorphisms (red line) on gene regulation. In the final case (right) the CRS polymorphism has 
altered the expression profile regulated by the CRS and perturbation with treatment 2 is now  
non-effective, a finding which may have clinical implications for individuals with this polymorphism 
(see: cis-Regulatory Sequence Variation and Drug Response Stratification). Finally, the first case (left) 
highlights the need for this experimental paradigm to include qrtPCR analysis in order to qualify that 
such changes in reporter gene quantities (either by treatments or by polymorphisms) are corroborated 
by changes in endogenous transcript quantity of the target gene. Demonstration of alterations in the 
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endogenous transcript quantity indicate the potential for alterations in biochemical events to be 
associated with the target genes product. 
6.2. Embryonic Stem Cell Targeting 
Despite high financial and time costs, embryonic stem cell targeting studies in mice are required to 
allow a full analysis of the role of CRSs in development and disease. Employing well defined strategies 
to knock-in or knock-out CRSs of interest, through the use of Cre-lox or Flp systems [89?93], 
researchers can define the effects of CRSs, and their polymorphisms on endogenous genes in an in vivo 
system that would be difficult to detect using the previously mentioned primary cell or transgenic 
strategies. In particular, the developmental role of a CRS may be assessed by knocking it out and 
analysing resultant changes in body plan, organ development or neuronal patterning. It is worth noting, 
however, that to date most CRSs are recognised as having modest effects on gene expression and 
therefore stable transgenic mouse models may only be used when the analysis of the effects of a SNP 
on CRS function is compelling and has been exhausted by the means described previously. 
6.3. A Question of Specificity? 
To date the majority of CRS studies utilising reporter constructs are conducted using exogenous 
promoters, and the use of transformed cell lines during analysis by reporter assay. Thus, a seriously 
underestimated but critical property of CRSs; namely, specificity in terms of promoter specificity and 
cell-type specificity is being overlooked in these cases. 
The principle behind CRS-promoter specificity lies in the fact that CRSs may be located within or 
beyond neighbouring genes therefore the interaction (e.g., CRS-promoter) that takes place during 
CRS-mediated transcription relies on the CRS preferentially recognising its specific promoters. 
Indeed, there are examples of this phenomenon whereby the enhancer required to drive the expression 
of the Sonic hedgehog (Shh) gene in the developing limb bud is found in the intron of a gene lying  
1 Mb from the Shh locus, called Lmbr1, which is also unaffected by its activity [94]. In addition, 
regulatory elements functioning in trans such as those found in Drosophila olfactory receptor genes 
serve as further evidence of this principle [95]. Whether CRS-promoter interactions are controlled and 
maintained by levels of chromatin flexibility [96], chromosomal location with the nucleus [97?100], 
the interaction of TFs and chromatin remodelling complexes [100], or perhaps a combination of these 
and undiscovered mechanisms does not alter the principle that CRS-promoter interactions must be 
specific for the appropriate regulation of their associated genes. 
CRS specificity to particular cell types is well documented and a defining feature of their mode of 
action. Hence experimental approaches aimed at defining the impact of a CRS and/or endogenous CRS 
variation should also consider the impact that different cell types may have on the ability of the chosen 
CRS to function accurately. Both ECR1 of TAC1 [10] and GAL5.1 of the Galanin gene [82] exhibit 
extreme cell-type dependent activity where they are only able to support reporter gene expression in a 
tiny subset of hypothalamic and amygdala and PVN (paraventricular nucleus) cells respectively [82]; 
representing a very small fraction of the total cells found within the animal. With this in mind it is 
essential that CRS characterisation studies include paradigms that most accurately reflect the 
expression of endogenous candidate genes in order to develop faithful models of CRS-mediated gene 
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regulation. Indeed, many of the reports of non-functionality of highly conserved sequences in the 
existing literature may stem from a failure to analyse these sequences within an appropriate in vivo or 
primary cell-derived model system in which the appropriate cellular components are active. 
7. Novel Considerations of cis-Regulatory Sequence Polymorphic Variation 
7.1. cis-Regulatory Sequence Variation and Drug Response Stratification 
Variation in drug response within the human population represents an important barrier to clinical 
drug development by an increasingly pressured pharmaceutical industry. Referred to as drug response 
stratification, the outcome is often rejection of the drug based on a lack of a significantly positive or 
unpredictable response. We propose that CRS variation may be a major causative or contributing 
factor to drug response stratification. Firstly, consider that the effect on any drug is reliant on its 
perturbation of a targeted biochemical process or of a receptor function. Modulation of receptor 
function results in alterations of downstream signal transduction systems that, in turn changes gene 
expression through CRS activation. Changes in the activity of these CRS, as a result of polymorphic or 
epigenetic variation, may have important consequences for the downstream effects of these drugs thus 
contributing to drug response stratification. Indeed, research has indicated that stratified responses to 
glucocorticoid treatments can result from cis-regulatory polymorphisms located near glucocorticoid 
target genes [101]. Further, non-coding SNPs have been identified which significantly inpact the IC50 
values and cytotoxicity of chemotherapeutic agents highlighting the potential for such SNPs to be used 
as markers for predicting drug responses. Characterisation of human genome variation may therefore 
allow genetic screening to determine the likelihood of a positive/negative drug response in advance of 
clinical trials. Implementation of this strategy will rely on detailed characterisation of CRSs and their 
variation in part by the techniques described above which are designed to dissect the precise 
biochemical events associated with CRS-mediated gene regulation. 
7.2. Genetic and Epigenetic Interaction within CRSs and Disease Susceptibility 
DNA methylation, the addition of methyl groups to CpG dinucleotides in the genomic sequence, is 
a heritable form of epigenetic gene regulation vital to cellular homeostasis and development [102]. The 
presence or absence of the methyl group has been shown to be affected by early life cues such as 
starvation or stress, and directly prevents TF-DNA binding thereby altering gene transcription. 
Furthermore, DNA methylation aberrations are associated with human disease [103]. If we consider 
this process with respect to CRSs that are critical to gene regulation, it is not unreasonable to conclude 
that CRSs methylation plays an important role in contributing to human pathologies. For example, it 
has been shown that methylation of a CRS involved in arginine vasopressin (AVP) gene expression 
can be altered by early life stress. This results in aberrant hormone secretion leading to changes in 
passive stress coping and memory [104]. We have also detected allelic variants within the  
GAL5.1 enhancer which renders it susceptible to DNA methylation through the introduction of a CpG 
sequence [82]. By contrast, analysis of the ECR1 sequence within CNR1 intron 2 shows the presence 
of an allelic variant that confers resistance to DNA methylation [85]. Considering the role that the 
Galanin and CNR1 genes play in appetite, mood and inflammatory pain these examples suggest the 
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presence of an interplay between genetic and epigenetic variation within CRSs that may have an 
important baring on our future ability to understand disease susceptibility. 
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